Quest Diagnostics Incorporated· DGX
🇺🇸 US · LargeSP500NYSE
- Price
- $237.14
- Day
- -0.94%
- Mkt Cap
- $26.17B
- 52W Range
- $171.18 – $247.19
- Volume
- 775.6K
- Beta
- 0.55
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Connor Clark and Lunn Investment Management Ltd. purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,113 shares of the medical research company's stock, valued at approximately $660,000. Other
Read full article
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read full article
Bank OZK purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 15,322 shares of the medical research company's stock, valued at approximately $3,247,000. Other institutional investors and hedge funds have also made changes to their
Read full article
Artia Global Partners LP purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE: DGX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 65,122 shares of the medical research company's stock, valued at approximately $13,803,000. Quest Diagnostics
Read full article
Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday. The stock traded as high as $246.00 and last traded at $243.9570, with a volume of 837684 shares changing hands. The stock had previously closed at $244.39. Analyst Upgrades and Downgrades A number of brokerages
Read full article
Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile tests purchased through Quest's consumer-initiated testing platform LONDON, Aug. 25, 2026 /PRNewswire/ -- Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform. Individuals now have the option to select the Humanity Biological Age add-on when purchasing select health profile tests from questhealth.com including Elite Health Profile, Men's and Women's Comprehensive Health Profiles, and Fitness Profile — Elite, with no additional blood draw needed.
Read full article
SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m.
Read full article
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10% indeterminate rate, so more patients can receive an actionable insight SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.
Read full article
SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14, 2026, at 10:00 a.m.
Read full article
Shares of Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen analysts that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating
Read full article
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read full article
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Read full article